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EclipseHolmiumLTMRhas reportedlyresultedin reductionof ischemic
symptomsin patientswith end-stageIschemiccardiomyopathy.However,









thenallowedto recoverand wererestudied(Day2) at l-week (n =4) and
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developadwhich is amallenoughto be introducedtransnaeelyin human
subjeofa(TNT).Oeeeasionally,trsnsnasalpassageisdifficult,eiaoeiatedwith
minordiscomfortor nasalmucosableeding.TocircumventheseIimitetiona,
we evafuatedthe uae of trananeaalincubationwith the new TNT probe
usingtwo differenttypes of nasalconduits.The first conduit is a hollow
plastictube which is introducedinto the nasalpassagewith subsequent
pessegeof the TNTprobethroughthis device.TheaacondConduitallows
aimultenaousintroductionof,ftreconduitandprobethusavoidingastep.This
customdevelopedconduitis a polyvinylchloridetubewitha distalnormally
closedlobedballendwhichselectivelyopeneto permitpassageof theTNT
probe.The proximalend of the thin walledtuba is ball shapedfor easier
probsinsertionandpassage.Westudied65 patientswithTNTdividedinto
3 groups.Thirtyeight patientswere intubatt+dwithouta nasalconduit,37
were Infubetadwith the first and 12 patientswith the secondgeneration
conduit.Transneealpeeeageof the prototypeprobewaapossiblein 76~0




witheaseasa oneetepmaneuverwiththe useof a newsecondgeneration
meal conduit.









stimulationi patientswith significantleft ventriculardysfunction(LVEFs
35%)weevaluateda populationof 70patients(56men),54 + 12yeareold,
including44withischemicheartdiseaae(IHD)and26withidiopathicdilated
cardiomyopathy(DCM).Radionuclideventriculogrephyincludeddetermina-
tionof LVEFat restandaftergradedinfusionof epinephrineor dobutemine
(inot).AverageLVEFvalueswere23 +7% at basellneand29+ 11%after
inotropicstimulation.
Duringa follow-upof 31 + 17months24 cardiacdeathsoccurred(13 in
IHDgroupand11in DCMgroup).Usinga cutoffof25%,inotropicLVEFwas
superiorto baselineLVEFindiscriminatingKaplanMeierestimatedsuwival.
Suwivalat 1, 2 and 3 years(95%Cl”for 3 years)weerespectively100%,
90%and86%(7I-1OO)for restLVEF? 25%,78%,69%and 61% (48-76)
for restLVEF< 25°A(p = 0.03),100%,91%and86%(77-99) for inotLVEF
? 25%and68%,56%and47?4(29-85)for inotLVEF< 25%(p < 0.0008).
$p~. $~







prognosticevaluationin patientswith importantleft ventriculardysfunction,
andmaybeuaefulin theselaetionof patientafor hearttransplant.
11073-52( DobLftSmineRadiOnuclideVentriculography:
Prediction of Ventricular Funotion Improvement





patients(pte)with ischemiccardiomyopathy(IC)dependingon the amount
of Contractilemyocerdialresewe.The useof low-dosedobutamine(DOB)
radionuclideventrfculogrsphy(RNV)intheassessmentoffunctionalcontrac-
tile resewehasnot beencriticallyevaluated.We prospectivelyatudisd35
ptswithIC(meanEF23 + 5%)andtriple-vesseldiseaseonemonthpriorto
CABG.All underwenta 2-dayprotocol:day 1- Tc99mseatamibi(SM)(25
mci)SPECTimagingat rest,performedfor viabilityeeoring(15aegments);
day2- RNVpriorto andduringinfusionof’5and10#k@gfmin of DOB.An
increaseof globalEFfromrestto DOB(AEF)wascalculated,andvalueof
10%wasconsideredas cutofffor predictivevalue.Twopts diedwithinone
monthofCABG.Therest(33pta)werefollowedfor 12+ 5 months.Ofthese,
16ahowedimprovement(AEFz 5%mean10+ 5%)and 17did not (AEF
< 5%mean-1 + 3%).Theresultspriorto CABGwere:
ImprovsdEF No improvedEF P
SM-ViabilityScore 7* 1 8k2 NS
Resting- EF (“A) 254C 5 22* 5 NS
EDV (ml) 193 l 50 212*49 NS
DOBAEF(%) 10*5 5*4 0.03
Thesensitivity,apecificify,positiveandnegativepredictivevaluesof DOB
RNVwere65%,92%,92%,and67%,respectively.Conclusions:DOBRNV
iaa usefulmethodto asseasandpredictfunctionalimprovementafterCABG
